Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans

Detalhes bibliográficos
Autor(a) principal: Pinto, Luzia Maria de Oliveira
Data de Publicação: 2017
Outros Autores: Azeredo, Elzinandes Leal de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/22837
Resumo: Autors: Grifoni A1, Pham J1, Sidney J1, O'Rourke PH1, Paul S1, Peters B1, Martini SR1, de Silva AD1,2, Ricciardi MJ3, Magnani DM3, Silveira CGT4, Maestri A4, Costa PR4, de-Oliveira-Pinto LM5, de Azeredo EL5, Damasco PV6, Phillips E7, Mallal S7, de Silva AM8, Collins M8, Durbin A9, Diehl SA10, Cerpas C11, Balmaseda A11, Kuan G12, Coloma J13, Harris E13, Crowe JE Jr14, Stone M15, Norris PJ15, Busch M15, Vivanco-Cid H16, Cox J17, Graham BS17, Ledgerwood JE17, Turtle L18,19,20, Solomon T19,21,22, Kallas EG4, Watkins DI3, Weiskopf D1, Sette A23. AUTOR INFORMATION:- 1 Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA. 2- Genetech Research Institute, Colombo, Sri Lanka. 3 - Department of Pathology, University of Miami Miller School of Medicine, Miami, FL. 4 - Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, Brazil. 5 - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 6 - Federal University of the State of Rio de Janeiro (UNIRIO). 7 - Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN. 8 - Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC. 9 - Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. 10 - University of Vermont, School of Medicine, Burlington, VT. 11 - National Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua. 12 - Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua. 13 - Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, USA. 14 - Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN. 15 - Blood Systems Research Institute, San Francisco, CA. 16 - Instituto de Investigaciones Medico-Biologicas, Universidad Veracruzana, Veracruz, Mexico. 17 - Vaccine Research Center, NIAID, NIH, Bethesda, MD. 18 - Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 19 - NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 20 - Tropical & Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, UK. 21 - Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 22 - Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. 23 - Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA alex@lji.org.
id CRUZ_2d291f27f78dbdab9b9fe59b86521f3d
oai_identifier_str oai:www.arca.fiocruz.br:icict/22837
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Pinto, Luzia Maria de OliveiraAzeredo, Elzinandes Leal de2017-10-17T11:55:22Z2017-10-17T11:55:22Z2017GRIFONI, Alba et al. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J. Virol. p. 1-56, Oct. 2017.https://www.arca.fiocruz.br/handle/icict/2283710.1128/JVI.01469-17Autors: Grifoni A1, Pham J1, Sidney J1, O'Rourke PH1, Paul S1, Peters B1, Martini SR1, de Silva AD1,2, Ricciardi MJ3, Magnani DM3, Silveira CGT4, Maestri A4, Costa PR4, de-Oliveira-Pinto LM5, de Azeredo EL5, Damasco PV6, Phillips E7, Mallal S7, de Silva AM8, Collins M8, Durbin A9, Diehl SA10, Cerpas C11, Balmaseda A11, Kuan G12, Coloma J13, Harris E13, Crowe JE Jr14, Stone M15, Norris PJ15, Busch M15, Vivanco-Cid H16, Cox J17, Graham BS17, Ledgerwood JE17, Turtle L18,19,20, Solomon T19,21,22, Kallas EG4, Watkins DI3, Weiskopf D1, Sette A23. AUTOR INFORMATION:- 1 Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA. 2- Genetech Research Institute, Colombo, Sri Lanka. 3 - Department of Pathology, University of Miami Miller School of Medicine, Miami, FL. 4 - Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, Brazil. 5 - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 6 - Federal University of the State of Rio de Janeiro (UNIRIO). 7 - Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN. 8 - Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC. 9 - Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. 10 - University of Vermont, School of Medicine, Burlington, VT. 11 - National Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua. 12 - Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua. 13 - Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, USA. 14 - Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN. 15 - Blood Systems Research Institute, San Francisco, CA. 16 - Instituto de Investigaciones Medico-Biologicas, Universidad Veracruzana, Veracruz, Mexico. 17 - Vaccine Research Center, NIAID, NIH, Bethesda, MD. 18 - Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 19 - NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 20 - Tropical & Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, UK. 21 - Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 22 - Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. 23 - Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA alex@lji.org.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil.Múltipla - ver em NotasWhile progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether pre-existing dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with Tetravalent Dengue Attenuated Vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors, but declines in DENV pre-exposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells form DENV pre-exposed donors selectively up-regulated granzyme B and PD1, as compared to DENV-naïve donors. Finally, we discovered that ZIKV structural proteins (E, prM and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how pre-existing DENV T cell immunity modulates ZIKA T cell responses is of great relevance as the two viruses often co-circulate and ZIKA virus has been spreading in geographical regions where DENV is endemic or hyper-endemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude and quality of the T cell response. Additionally we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing towards important implications for vaccine design against this global threat.engAmerican Society for MicrobiologyDengueVírus ZikaHeterologus immunityCross-reactivityImmunodominanceZIKVDengue virus (DENV)Zika virusFlavirusT CellsPrior Dengue virus exposure shapes T cell immunity to Zika virus in humansinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleNãoNão publicadoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/22837/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALelzinandes_azeredo_etal_IOC_2017.pdfelzinandes_azeredo_etal_IOC_2017.pdfapplication/pdf3797932https://www.arca.fiocruz.br/bitstream/icict/22837/2/elzinandes_azeredo_etal_IOC_2017.pdfce8257c59b7c5772c5fbf09d17ad53c4MD52TEXTelzinandes_azeredo_etal_IOC_2017.pdf.txtelzinandes_azeredo_etal_IOC_2017.pdf.txtExtracted texttext/plain91353https://www.arca.fiocruz.br/bitstream/icict/22837/3/elzinandes_azeredo_etal_IOC_2017.pdf.txt594c1f40a6d912045ef85a75f9baebbbMD53icict/228372018-12-30 20:26:16.44oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352018-12-30T22:26:16Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
title Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
spellingShingle Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
Pinto, Luzia Maria de Oliveira
Dengue
Vírus Zika
Heterologus immunity
Cross-reactivity
Immunodominance
ZIKV
Dengue virus (DENV)
Zika virus
Flavirus
T Cells
title_short Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
title_full Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
title_fullStr Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
title_full_unstemmed Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
title_sort Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans
author Pinto, Luzia Maria de Oliveira
author_facet Pinto, Luzia Maria de Oliveira
Azeredo, Elzinandes Leal de
author_role author
author2 Azeredo, Elzinandes Leal de
author2_role author
dc.contributor.author.fl_str_mv Pinto, Luzia Maria de Oliveira
Azeredo, Elzinandes Leal de
dc.subject.other.pt_BR.fl_str_mv Dengue
Vírus Zika
topic Dengue
Vírus Zika
Heterologus immunity
Cross-reactivity
Immunodominance
ZIKV
Dengue virus (DENV)
Zika virus
Flavirus
T Cells
dc.subject.en.pt_BR.fl_str_mv Heterologus immunity
Cross-reactivity
Immunodominance
ZIKV
Dengue virus (DENV)
Zika virus
Flavirus
T Cells
description Autors: Grifoni A1, Pham J1, Sidney J1, O'Rourke PH1, Paul S1, Peters B1, Martini SR1, de Silva AD1,2, Ricciardi MJ3, Magnani DM3, Silveira CGT4, Maestri A4, Costa PR4, de-Oliveira-Pinto LM5, de Azeredo EL5, Damasco PV6, Phillips E7, Mallal S7, de Silva AM8, Collins M8, Durbin A9, Diehl SA10, Cerpas C11, Balmaseda A11, Kuan G12, Coloma J13, Harris E13, Crowe JE Jr14, Stone M15, Norris PJ15, Busch M15, Vivanco-Cid H16, Cox J17, Graham BS17, Ledgerwood JE17, Turtle L18,19,20, Solomon T19,21,22, Kallas EG4, Watkins DI3, Weiskopf D1, Sette A23. AUTOR INFORMATION:- 1 Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA. 2- Genetech Research Institute, Colombo, Sri Lanka. 3 - Department of Pathology, University of Miami Miller School of Medicine, Miami, FL. 4 - Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, Brazil. 5 - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 6 - Federal University of the State of Rio de Janeiro (UNIRIO). 7 - Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN. 8 - Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC. 9 - Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. 10 - University of Vermont, School of Medicine, Burlington, VT. 11 - National Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua. 12 - Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua. 13 - Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, USA. 14 - Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN. 15 - Blood Systems Research Institute, San Francisco, CA. 16 - Instituto de Investigaciones Medico-Biologicas, Universidad Veracruzana, Veracruz, Mexico. 17 - Vaccine Research Center, NIAID, NIH, Bethesda, MD. 18 - Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 19 - NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 20 - Tropical & Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, UK. 21 - Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. 22 - Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. 23 - Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA alex@lji.org.
publishDate 2017
dc.date.accessioned.fl_str_mv 2017-10-17T11:55:22Z
dc.date.available.fl_str_mv 2017-10-17T11:55:22Z
dc.date.issued.fl_str_mv 2017
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv GRIFONI, Alba et al. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J. Virol. p. 1-56, Oct. 2017.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/22837
dc.identifier.doi.pt_BR.fl_str_mv 10.1128/JVI.01469-17
identifier_str_mv GRIFONI, Alba et al. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J. Virol. p. 1-56, Oct. 2017.
10.1128/JVI.01469-17
url https://www.arca.fiocruz.br/handle/icict/22837
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/22837/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/22837/2/elzinandes_azeredo_etal_IOC_2017.pdf
https://www.arca.fiocruz.br/bitstream/icict/22837/3/elzinandes_azeredo_etal_IOC_2017.pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
ce8257c59b7c5772c5fbf09d17ad53c4
594c1f40a6d912045ef85a75f9baebbb
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008972714606592